# IL-10 (Interleukin-10): Complete Research Profile — The Master Anti-Inflammatory Cytokine, IL-10RA/IL-10RB-JAK1-TYK2-STAT3 Signaling, Immunological Homeostasis, and Tumor Microenvironment Research (2026)
Overview
Interleukin-10 (IL-10) is a pleiotropic cytokine widely recognized as the master regulator of anti-inflammatory immune responses. Discovered in 1989 by Fiorentino and colleagues as "cytokine synthesis inhibitory factor" (CSIF), IL-10 has since been established as an indispensable brake on excessive inflammation — preventing tissue damage from hyperactivated immune responses while simultaneously supporting immunological tolerance, B cell differentiation, and specific aspects of anti-tumor immunity.
Unlike the pro-inflammatory cytokines covered elsewhere on this platform — including TNF-α, IL-1β, IL-6, IFN-γ, and IL-17A — IL-10 operates predominantly as a counter-regulatory signal, limiting the duration and magnitude of innate and adaptive immune responses. Its biology sits at the intersection of infection resolution, autoimmune disease, chronic inflammation, and cancer immunology, making it one of the most studied cytokines in biomedical research.
For research use only (RUO). All content describes in vitro and ex vivo laboratory investigations.
---
Molecular Biology: Structure and Gene
Human IL-10 is encoded by the IL10 gene on chromosome 1q31-1q32, comprising five exons. The mature secreted protein is a 178-amino-acid polypeptide (after cleavage of the 18-residue signal peptide) with a molecular weight of approximately 18-19 kDa per monomer.
Homodimeric Architecture
IL-10 adopts a distinctive domain-swapped homodimeric structure — one of the few cytokines to do so. The functional form is a symmetric 36-38 kDa homodimer in which the two monomers are intertwined: each monomer contributes six α-helices (A through F), and each functional domain of the dimer comprises helices A-D from one chain and helices E-F from the other. This domain-swapped architecture is critical for receptor engagement and biological activity.
This structural arrangement classifies IL-10 as a member of the class-2 cytokine superfamily (also called the IL-10 family or type II cytokine family), which includes IL-19, IL-20, IL-22, IL-24, IL-26, IL-28A, IL-28B, and IL-29 — though IL-10 itself has unique receptor specificity and a distinct immunological role compared to its family members.
Glycosylation and Post-Translational Modifications
Recombinant IL-10 expressed in mammalian systems carries N-linked glycosylation, though the carbohydrate moieties are not strictly required for receptor binding or bioactivity. Bacterial expression systems (E. coli) yield non-glycosylated IL-10 that retains full biological potency in vitro, making bacterially-derived recombinant human IL-10 a practical research reagent.
---
The IL-10 Receptor Complex
IL-10 signals through a tetrameric receptor complex composed of two chains: IL-10RA (IL-10Rα, CD210a) and IL-10RB (IL-10Rβ, CD210b). The functional complex contains two copies of each subunit — a (IL-10RA)₂(IL-10RB)₂ heterotetramer.
IL-10RA (IL-10Rα, CD210a)
- •Gene: IL10RA
- •Expression: Restricted primarily to hematopoietic cells — monocytes, macrophages, dendritic cells, T cells, B cells, NK cells, mast cells
- •Function: High-affinity ligand-binding subunit; primarily responsible for IL-10 recognition and specificity
- •Signaling partner: Constitutively associated with JAK1
- •Clinical relevance: Loss-of-function mutations in IL10RA cause very early-onset inflammatory bowel disease (VEO-IBD) in humans
IL-10RB (IL-10Rβ, CD210b)
- •Gene: IL10RB
- •Expression: Ubiquitous; expressed on virtually all nucleated cells
- •Function: Shared signaling subunit (auxiliary chain); no high-affinity IL-10 binding on its own
- •Signaling partner: Constitutively associated with TYK2
- •Shared usage: IL-10RB is the shared β-subunit for multiple IL-10 family cytokines including IL-22, IL-26, IL-28A/B, and IL-29
The requirement for IL-10RB explains why IL-10 can signal through IL-10RA even though IL-10RA alone is insufficient for downstream JAK-STAT activation.
---
JAK1-TYK2-STAT3 Signaling Cascade
IL-10 signaling through its receptor is relatively linear compared to the complex branching of receptors like gp130 (used by IL-6) or the TNFR superfamily.
Signal Initiation
1. IL-10 homodimer engages two IL-10RA chains with high affinity (Kd ~0.2-0.5 nM)
2. The IL-10/IL-10RA complex then recruits two IL-10RB chains, forming the (IL-10RA)₂(IL-10RB)₂ heterotetrameric complex
3. Receptor assembly induces transphosphorylation of JAK1 (associated with IL-10RA) and TYK2 (associated with IL-10RB)
STAT3 Activation
4. Activated JAK1/TYK2 phosphorylate specific tyrosine residues in the intracellular domain of IL-10RA (primarily Y446 and Y496), creating docking sites for STAT3 SH2 domains
5. Recruited STAT3 is phosphorylated on Y705 by JAK1/TYK2
6. Phospho-STAT3 (pY705) forms homodimers via reciprocal SH2-pY705 interactions
7. pSTAT3 homodimers translocate to the nucleus and bind STAT3-response elements (GAS motifs) in target gene promoters
8. Downstream transcriptional activation of anti-inflammatory genes including:
- SOCS3 (suppressor of cytokine signaling 3) — negative feedback
- BCL3 — anti-inflammatory transcription factor
- TNFAIP3 (A20) — NF-κB inhibitor
- IL10 itself — autocrine amplification loop
Negative Regulation
SOCS3, induced by IL-10/STAT3 signaling, provides a critical negative feedback loop by binding and inhibiting JAK1/TYK2, attenuating downstream STAT3 activation. This limits the duration of IL-10 responses and prevents excessive immunosuppression.
Notably, the STAT3 activation profile of IL-10 is distinct from IL-6-family cytokines (which signal through gp130): IL-10 predominantly activates STAT3 without co-activating STAT1 or the MAPK/ERK pathways that are characteristic of IL-6 trans-signaling via soluble gp130. This difference in signal integration explains why IL-10 and IL-6 — both STAT3-activating cytokines — have such divergent biological outcomes.
---
Cellular Sources
IL-10 is produced by a remarkably diverse array of immune cell types, allowing it to function as a universal immunological brake:
| Cell Type | Context of IL-10 Production |
|---|---|
| Macrophages (M2/TAMs) | Anti-inflammatory polarization, tissue repair contexts |
| Regulatory T cells (Tregs) | FOXP3+ Tregs are major IL-10 sources in periphery and TME |
| Th2 cells | Type 2 immune responses, allergy |
| Th1 cells | Self-limiting autocrine brake during strong Th1 responses |
| B regulatory cells (Bregs) | IL-10-competent B cells suppress inflammation |
| Dendritic cells | Tolerogenic DCs, after repeated antigen exposure |
| Monocytes | Especially following TLR activation (M2-polarizing signals) |
| Mast cells | Chronic inflammation sites |
| NK cells | Following activation |
| Innate lymphoid cells (ILCs) | ILC2s, regulatory ILCs |
This broad source spectrum means that IL-10 operates at multiple stages of immune responses — from early innate reactions to late adaptive resolution phases.
---
Key Immunological Functions
1. Macrophage Deactivation and Inhibition of Pro-Inflammatory Cytokines
IL-10's most potent function is the suppression of activated macrophage and monocyte secretory programs. Through STAT3, IL-10 directly inhibits the production of:
- •TNF-α
- •IL-1β (including NLRP3 inflammasome-mediated processing)
- •IL-6
- •IL-12 (p70 and p40 subunits)
- •IL-18
- •MHC class II surface expression (downregulates antigen presentation)
- •Reactive oxygen species (ROS) production
- •Nitric oxide synthase (iNOS) expression
This macrophage-suppressive activity is the original function for which IL-10 was characterized — as "cytokine synthesis inhibitory factor" it was first identified as a Th2-derived factor that blocked Th1 cytokine production by macrophages.
2. B Cell Differentiation and Immunoglobulin Class Switching
IL-10 promotes B cell survival, proliferation, and terminal differentiation into plasma cells. Specific functions include:
- •Supporting IgG, IgA, and IgM production
- •Promoting IgG1 and IgG3 class switching in humans
- •Enhancing B cell survival (anti-apoptotic via Bcl-2/Bcl-xL upregulation)
- •Supporting the germinal center reaction in conjunction with CD40L signaling
IL-10-producing regulatory B cells (Bregs) represent a functionally important immunosuppressive population, though the phenotypic definition of Bregs remains an active area of investigation.
3. T Cell Regulation
IL-10's effects on T cells are context-dependent:
- •CD4+ Th1 inhibition: IL-10 inhibits IL-12 production from APCs, indirectly suppressing Th1 polarization and IFN-γ production
- •Th17 modulation: IL-10 counteracts IL-17A and IL-17F production in inflammatory settings
- •Treg support: IL-10/STAT3 signaling reinforces FOXP3 expression and Treg suppressive function
- •Cytotoxic T cell paradox: Paradoxically, IL-10 can enhance CD8+ cytotoxic T cell function — particularly when used in PEGylated form (pegilodecakin) — by mechanisms still under investigation
4. Dendritic Cell Regulation
IL-10 promotes tolerogenic dendritic cell (DC) phenotypes by:
- •Downregulating MHC class II, CD80, and CD86 co-stimulatory molecules
- •Inhibiting IL-12p70 secretion (required for Th1 priming)
- •Promoting DC differentiation toward IL-10-secreting tolerogenic states
This creates an autocrine amplification loop in which IL-10 promotes tolerogenic DC phenotypes that themselves produce more IL-10.
---
IL-10 in Autoimmune Disease Research
Inflammatory Bowel Disease (IBD) Models
The IL10 knockout mouse is one of the most informative genetic models in immunology: IL10−/− mice on most backgrounds spontaneously develop severe colitis resembling human IBD, establishing that IL-10 is non-redundantly required for maintaining intestinal immune homeostasis. The intestinal epithelium is continuously exposed to commensal bacteria, and without IL-10-mediated restraint, this leads to uncontrolled Th1/Th17 responses and colonic inflammation.
Consistent with the mouse genetics, loss-of-function mutations in IL10, IL10RA, or IL10RB cause very early-onset inflammatory bowel disease (VEO-IBD) in human infants — one of the most compelling human genetics validations of any cytokine pathway (PMID: 21483000).
Rheumatoid Arthritis and Systemic Inflammation
In established inflammatory settings such as rheumatoid arthritis (RA), IL-10 is paradoxically present at elevated levels in synovial fluid — representing an endogenous but insufficient counter-regulatory response. Macrophage- and Treg-derived IL-10 in the RA joint attempts to restrain TNF-α and IL-1β-driven inflammation but is overwhelmed by the magnitude of the inflammatory drive.
Systemic Lupus Erythematosus (SLE)
IL-10 biology in lupus is uniquely complex: elevated systemic IL-10 promotes B cell hyperstimulation and autoantibody production (a pro-disease role), while simultaneously suppressing innate inflammatory programs. This dual role makes IL-10 blockade a complex therapeutic consideration in SLE research models.
---
IL-10 in the Tumor Microenvironment
The role of IL-10 in cancer represents one of the most intensively researched — and paradoxical — areas of cytokine biology. IL-10 has both pro-tumor immunosuppressive functions and unexpected anti-tumor activities depending on context.
Immunosuppressive Functions in the TME
In established solid tumors, IL-10 is a major immunosuppressive mediator:
- •Myeloid-derived suppressor cells (MDSCs): MDSCs are potent IL-10 producers that suppress CD8+ T cell function and promote Treg expansion via IL-10 and TGF-β1 co-secretion
- •Tumor-associated macrophages (TAMs): M2-polarized TAMs produce IL-10 to suppress CD8+ effector responses and maintain immune exclusion
- •T cell exhaustion: In glioblastoma, a spatially localized subset of IL-10-releasing myeloid cells drives T cell dysfunction in mesenchymal tumor regions ()
- •PD-L1 regulation: IL-10/STAT3 signaling can upregulate PD-L1 expression on myeloid cells, further restraining anti-tumor T cell responses
The Paradox: IL-10 and CD8+ T Cell Enhancement
Counterintuitively, systemic IL-10 — particularly in PEGylated form — can enhance rather than suppress CD8+ T cell responses in cancer patients. PEGylated IL-10 (pegilodecakin/AM0010) induces:
- •Systemic expansion of CD8+ T cells, including tumor-infiltrating lymphocytes (TILs)
- •Increased granzyme B and perforin expression in CD8+ T cells
- •Elevated systemic IFN-γ secretion
- •Expansion of LAG-3+ PD-1+ CD8+ T cell populations
This activity is attributed to direct IL-10 signaling on CD8+ T cells via their IL-10R, independent of IL-10's suppressive effects on myeloid cells. The route of administration, dose, and pharmacokinetic profile appear critical in determining which arm of IL-10 biology predominates.
---
Recombinant IL-10 and Pegilodecakin Research
Recombinant Human IL-10 (rhIL-10)
Recombinant human IL-10 (rhIL-10) is a standard research tool for:
- •In vitro macrophage deactivation assays: Adding rhIL-10 to LPS-stimulated macrophages suppresses TNF-α, IL-1β, and IL-6 secretion — a core experimental paradigm for studying anti-inflammatory pathways
- •Treg induction protocols: IL-10 supports the maintenance and function of FOXP3+ regulatory T cells in culture
- •Tolerogenic DC generation: rhIL-10 combined with IL-4 generates tolerogenic DCs for immunological research
- •STAT3 reporter assays: IL-10 is used as a positive control for STAT3 phosphorylation (pY705) in cell-based assays
- •B cell culture: Supporting plasma cell differentiation in ex vivo immunoglobulin production studies
Pegilodecakin (AM0010 / LY3500518)
Pegilodecakin is PEGylated recombinant human IL-10, developed to extend the plasma half-life of IL-10 from minutes (native) to days. Its development provided key insights into IL-10 biology at the systemic level:
- •Phase 1 activity: Pegilodecakin demonstrated objective anti-tumor responses in renal cell carcinoma and uveal melanoma (PMID: 30790069)
- •CD8+ T cell induction: Systemic administration induced polyclonal CD8+ T cell expansion, granzyme B upregulation, and IFN-γ elevation (PMID: 30423297)
- •ICI combination studies: Pegilodecakin combinations with anti-PD-1 agents (pembrolizumab, nivolumab) showed activity signals in RCC but did not improve outcomes in NSCLC trials
- •CAR-T enhancement: In vitro and in vivo data suggest pegilodecakin can enhance CAR-T cell cytotoxicity, potentially through IL-10-mediated T cell metabolic reprogramming
---
IL-10 Family Cytokines: Structural Relatives
IL-10 shares structural and functional similarities with several related cytokines that also signal through shared receptor components:
| Cytokine | Receptor | Shared Chain | Primary Function in Research |
|---|---|---|---|
| IL-10 | IL-10RA + IL-10RB | IL-10RB | Anti-inflammatory, immunological homeostasis |
| IL-19 | IL-20RA + IL-20RB | IL-20RB | Skin inflammation, keratinocyte biology |
| IL-20 | IL-20RA + IL-20RB or IL-22RA1 + IL-20RB | IL-20RB | Psoriasis, skin homeostasis |
| IL-22 | IL-22RA1 + IL-10RB | IL-10RB | Epithelial barrier protection, mucosal immunity |
| IL-24 | IL-20RA + IL-20RB or IL-22RA1 + IL-20RB | — | Wound healing, cancer suppression |
| IL-26 | IL-20RA + IL-10RB | IL-10RB | Antimicrobial immunity (absent in rodents) |
| IL-28A/B (IFN-λ2/3) | IFNLR1 + IL-10RB | IL-10RB | Anti-viral, type III interferon activity |
| IL-29 (IFN-λ1) | IFNLR1 + IL-10RB | IL-10RB | Anti-viral, type III interferon activity |
The shared usage of IL-10RB across multiple family members means that genetic disruption of IL-10RB has far broader immunological consequences than IL-10RA disruption alone.
---
Trained Immunity and IL-10 Antagonism
A 2024 study in the Journal of Leukocyte Biology demonstrated that IL-10 inhibits trained immunity in primary human monocytes — suppressing the epigenetic and metabolic reprogramming induced by β-glucan or BCG that normally confers non-specific innate immune memory (PMID: 39531639). STAT3 inhibition reversed the IL-10-mediated block on trained immunity, suggesting that STAT3 is mechanistically required for this function.
This finding has implications for understanding why IL-10-rich environments (e.g., certain tumor microenvironments or chronic infection states) impair innate immune memory and reduce the effectiveness of trained immunity-based vaccination strategies.
---
IL-10 Deficiency Models and Viral IL-10 Homologs
IL-10 Knockout Models
- •IL-10−/− mice (C57BL/6 background): Develop spontaneous colitis; indispensable model for studying intestinal immune homeostasis and IBD
- •Cell-specific IL-10 knockouts: Myeloid-specific (LysM-Cre × IL-10fl/fl), T cell-specific (CD4-Cre × IL-10fl/fl), and Treg-specific IL-10 KOs each produce distinct inflammatory phenotypes, revealing the relative contributions of each source
- •IL-10R knockout mice: Phenocopy IL-10 KO more severely due to loss of both IL-10 and IL-10 family member signaling
Viral IL-10 Homologs
Several herpesviruses encode viral IL-10 (vIL-10) homologs that mimic host IL-10 function to evade immune surveillance:
- •Epstein-Barr Virus (EBV): Encodes BCRF1 (vIL-10), a secreted protein with 70-84% amino acid identity to human IL-10 at the receptor-binding domain. EBV-vIL-10 binds IL-10R and signals via STAT3, suppressing anti-viral immune responses — likely contributing to EBV immune evasion and potentially to EBV-associated lymphomagenesis
The existence of viral IL-10 homologs underscores the evolutionary pressure to co-opt this cytokine's potent immunosuppressive function.
---
Research Applications Summary
| Application | Description | Key Readout |
|---|---|---|
| Macrophage deactivation assay | rhIL-10 added to LPS-stimulated PBMC/macrophage cultures | Suppression of TNF-α, IL-1β, IL-6 by ELISA |
| STAT3 phosphorylation | Positive control for pSTAT3(Y705) detection | Western blot, flow cytometry (pSTAT3) |
| Tolerogenic DC generation | IL-10 + GM-CSF or IL-4 culture protocols | Reduced CD80/CD86, IL-12 secretion |
| IBD mouse model studies | IL-10 KO or anti-IL-10 neutralization | Colitis scoring, histology, cytokine profiling |
| TME immunosuppression profiling | IL-10 detection in tumor-conditioned media | IL-10 ELISA, single-cell RNA-seq (IL10 expression) |
| Treg maintenance | IL-10 supplementation in Treg expansion cultures | FOXP3 expression, suppression assays |
| CD8+ T cell studies | IL-10 effects on T cell activation/exhaustion | Granzyme B, IFN-γ, LAG-3, PD-1 by flow cytometry |
---
Key Research Takeaways
1. IL-10 is not simply immunosuppressive — its effects are cell-type and context dependent, with potent immunostimulatory activity on CD8+ T cells at systemic levels
2. The IL-10RA/IL-10RB-JAK1/TYK2-STAT3 pathway is the canonical and near-exclusive signaling axis downstream of IL-10
3. SOCS3 induction provides critical negative feedback limiting IL-10/STAT3 signaling duration
4. The IL10−/− mouse colitis model remains one of the most informative genetic tools in mucosal immunology research
5. IL-10 in the TME functions primarily as an immunosuppressive cytokine through myeloid cell and Treg production, but PEGylated IL-10 (pegilodecakin) demonstrates paradoxical CD8+ T cell enhancement at systemic doses
6. STAT3 is mechanistically required for IL-10-mediated inhibition of trained immunity, revealed in 2024 studies
---
For research use only. IL-10 and related research reagents described in this article are intended for in vitro and ex vivo laboratory investigations only. This content does not constitute medical advice or clinical recommendations.